Ovid Therapeutics, Inc. (OVID)

2.375 -0.10 (-3.85%) USD  |  NASDAQ  |  Oct 22, 16:00
2.375 0.00 (0.00%) After-Hours: 20:00
More

Ovid Therapeutics EPS Diluted (Quarterly) : -0.076 for June 30, 2026

EPS Diluted (Quarterly) Chart

Historical EPS Diluted (Quarterly) Data

View and export this data back to 2017. Start Trial.
Date Value
June 30, 2026 -0.076
March 31, 2026 -0.1248
December 31, 2025 0.1183
September 30, 2025 -0.171
June 30, 2025 -0.0659
March 31, 2025 -0.1441
December 31, 2024 -0.1303
September 30, 2024 -0.1973
June 30, 2024 0.1202
March 31, 2024 -0.1654
December 31, 2023 -0.2168
September 30, 2023 -0.1593
June 30, 2023 -0.1759
March 31, 2023 -0.1895
December 31, 2022 -0.1632
September 30, 2022 -0.1699
June 30, 2022 -0.2072
March 31, 2022 -0.229
December 31, 2021 -0.369
Date Value
September 30, 2021 -0.1676
June 30, 2021 -0.2328
March 31, 2021 2.532
December 31, 2020 -0.3442
September 30, 2020 -0.2765
June 30, 2020 -0.4056
March 31, 2020 -0.3661
December 31, 2019 -0.3453
September 30, 2019 -0.432
June 30, 2019 -0.3375
March 31, 2019 -0.455
December 31, 2018 -0.5236
September 30, 2018 -0.5262
June 30, 2018 -0.53
March 31, 2018 -0.5357
December 31, 2017 -0.45
September 30, 2017 -0.38
June 30, 2017 -0.57
March 31, 2017 -1.350

EPS Diluted (Quarterly) Range, Past 5 Years

View EPS Diluted (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

EPS Diluted (Quarterly) Benchmarks

View EPS Diluted (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 0.1822
Alnylam Pharmaceuticals, Inc. 1.207
Anika Therapeutics, Inc. 0.2412
Savara, Inc. -0.1587
Vericel Corp. 0.0422

EPS Diluted (Quarterly) Related Metrics

Net Income (Quarterly) -15.01M
Revenue (Quarterly) 0.733M
Total Expenses (Quarterly) 15.74M
Enterprise Value 351.84M
Gross Profit Margin (Quarterly) 97.82%
Profit Margin (Quarterly) -2.05K%
Earnings Yield -10.67%
Normalized Earnings Yield -3.095